All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.

The GvHD Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

A global education and awareness initiative that provides patients and caregivers with information and resources to support them on their journey with graft-versus-host disease.

Visit Know GvHD

Join us in supporting GvHD Day on February 17

  TRANSLATE

The GvHD Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the GvHD Hub cannot guarantee the accuracy of translated content. The GvHD Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
Visit:
ALL Hub

ALL Hub

AML Hub

AML Hub

Lupus Hub

Lupus Hub

Lymphoma Hub

Lymphoma Hub

MPN Hub

MPN Hub

Multiple Myeloma

Multiple Myeloma Hub

PsOPsA Hub

PsOPsA Hub

LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
Steering CommitteeAbout UsNewsletterContact

Brought to you by

Scientific Education Support logo

The GvHD Hub is an independent medical education platform, sponsored by Medac and supported through grants from Sanofi and Therakos. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.

TypesTherapeuticsCongressesTrialsExpert OpinionsEducational ResourcesDRUG UPDATES
2020-06-18T09:25:24.000Z

REACH2: What patients with steroid-refractory acute GvHD respond best to ruxolitinib?

By Claire Baker, Amalia Zachariadis
Featured
Robert Zeiser
Jun 18, 2020
Share:

Bookmark this article

During the 25th Congress of the European Hematology Association (EHA), the GvHD Hub spoke to Robert Zeiser, Medical Center – University of Freiburg, Freiburg, DE about the REACH2 clinical trial. REACH 2 is a phase III study evaluating ruxolitinib vs best available therapy in patients with corticosteroid-refractory acute GvHD following allogeneic stem cell transplantation.

We asked: What patients with steroid-refractory acute GvHD respond best to ruxolitinib?

REACH2: What patients with steroid-refractory acute GvHD respond best to ruxolitinib?

More about...
EHA 2020Graft-versus-host diseaseREACH2RuxolitinibSteroid-refractory GvHD

Your opinion matters

HCPs, what is your preferred format for educational content on the GvHD Hub?
19 votes - 52 days left ...

Related articles

Add bookmark

Comparison of ruxolitinib with other therapies for steroid-refractory acute GvHD

A phase III study REACH2 comparing the efficacy and safety of ruxolitinib with nine commonly used therapies in patients with glucocorticoid-refractory aGvHD

May 25, 2020
Add bookmark

Comparison of ruxolitinib with other therapies for steroid-refractory acute GvHD

A phase III study REACH2 comparing the efficacy and safety of ruxolitinib with nine commonly used therapies in patients...

May 25, 2020
Add bookmark

Practice-changing abstracts at #ASCO20 and EHA 2020

Interview with GvHD Hub Co-Chair, Mohamad Mohty, providing an overview of the practice-changing abstracts from this year's virtual ASCO Annual Meeting and EHA Annual Congress.

Sep 9, 2020
Add bookmark

Practice-changing abstracts at #ASCO20 and EHA 2020

Interview with GvHD Hub Co-Chair, Mohamad Mohty, providing an overview of the practice-changing abstracts from this year's virtual ASCO Annual...

Sep 9, 2020

Newsletter

Subscribe to get the best content related to GvHD delivered to your inbox